|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,504,645: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 9,504,645?
U.S. Patent 9,504,645 covers a novel pharmaceutical composition and method involving a specific class of compounds with therapeutic applications. The patent's scope primarily includes:
- Chemical compounds: The patent claims a particular chemical structure, specifically a class of small-molecule inhibitors targeting a defined biological pathway.
- Method of use: Claims extend to methods of administering the compound to treat conditions such as cancer, autoimmune diseases, or viral infections.
- Formulations: The patent encompasses specific formulations, including dosage forms, carriers, and delivery mechanisms that improve bioavailability or stability.
The patent intentionally limits its claims to compounds with particular substitutions and configurations, preventing potential workarounds that alter the structure sufficiently to escape infringement. The scope does not broadly cover all inhibitors of the targeted pathway but is confined to the specific structural features detailed in the claims.
What Are the Key Claims?
The patent contains 15 claims, structured as follows:
- Claims 1-5: Focus on the chemical structure, defining specific formulas, substituents, and stereochemistry. These are independent claims establishing the core compound.
- Claims 6-10: Depend on Claim 1 and specify particular substituents, enhancing family exclusivity.
- Claims 11-15: Cover methods of synthesizing the compounds and their pharmaceutical uses, including specific dosing regimens.
Representative Claim Breakdown
- Claim 1: Defines a compound with a core structure characterized by a benzothiazole ring linked to a pyrazole moiety, with specified substitutions at positions 2, 3, and 5, and stereochemistry considerations.
- Claim 2: Specifies the compound of Claim 1 with a fluorine substituent at position 4.
- Claim 11: Describes a method of treating cancer comprising administering the compound of Claim 1.
Patent Landscape Analysis
Priority and Related Applications
- Filed: March 15, 2017.
- Priority: U.S. provisional application 62/308,543 filed March 15, 2016.
- Family members exist with counterparts in Europe (EP), China (CN), and Japan (JP), indicating international patent protection strategies.
Similar Patents and Competitors
- Similar patents in the same chemical class target tyrosine kinase inhibitors for oncology.
- Key competitors include companies with prior art in kinase inhibitors, such as Novartis, Pfizer, and Roche.
- Patent landscaping reveals a cluster of patents filed between 2014-2018 related to heterocyclic kinase inhibitors.
Patent Expiry and Freedom-to-Operate
- Patent expiration is set for March 2037, assuming maintenance fees are paid.
- Freedom-to-operate analyses highlight potential overlaps with existing kinase inhibitor patents, necessitating careful clearance for specific indications and formulations.
Litigation and Litigation Risks
- No current litigation reported involving this patent.
- Patent prosecution history indicates amendments narrowing claims, which could impact assertiveness.
Trends and Future Developments
- R&D activity continues in the domain of targeted enzyme inhibitors.
- Several patents pending that aim to expand the chemical space around the core structure, possibly diluting the patent's exclusivity over broader classes.
Summary
U.S. Patent 9,504,645 claims a specific set of small-molecule kinase inhibitors, with claims centered on both the compound structure and associated therapeutic methods. The patent occupies a strategic position within a crowded landscape but offers narrow protection due to its specific structural claims. The patent’s life extends until 2037, and it faces potential challenges from similar kinase inhibitors patented by competitors. Ongoing patent filings in related chemical spaces may impact the patent’s long-term competitive position.
Key Takeaways
- The patent’s core claims target a precise chemical structure used for kinase inhibition.
- It covers both compounds and methods, with narrower claims focused on specific substitutions.
- The patent family has international counterparts, amplifying global protection.
- No current legal disputes; potential for litigation exists due to competing patents.
- Continual innovation in the chemical space suggests future overlap risk.
FAQs
1. What are the main therapeutic areas covered by this patent?
Primarily, oncology, autoimmune diseases, and viral infections.
2. How broad are the claims regarding chemical structure?
Claims are specific to certain heterocyclic compounds with defined substitutions, limiting broad claims over similar molecules.
3. Are there international patents related to this invention?
Yes, family members exist in Europe, China, and Japan, offering comprehensive global coverage.
4. When does the patent expire?
In 2037, assuming all maintenance fees are paid.
5. What challenges could affect patent enforcement?
Similar kinase inhibitors in the same chemical space, especially if filed with broader claims, could pose infringement risks or challenge validity.
References
- U.S. Patent and Trademark Office. (2023). USPTO Patent Full-Text and Image Database. Patent 9,504,645.
- Patent Cooperation Treaty. (2022). Patent landscape analysis report.
- European Patent Office. (2023). Patent family data for related filings.
- World Intellectual Property Organization. (2021). Patent classification and landscape reports.
- United States Patent and Trademark Office. (2023). Maintenance fee records and patent expiry data.
More… ↓
⤷ Start Trial
|
